Phase I trial of FOLFOXIRI in combination with Panitumumab as first-line treatment of RAS wild-type metastatic colorectal cancer (JACCRO CC-14)

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter A. Tsuji
Citation Annals of Oncology (2016) 27 (2): 1-85. 10.1093/annonc/mdw199
Authors A. Tsuji1, M. Nakamura2, M. Ogawa3, H. Satake4, T. Kotake4, Y. Hatachi4, A. Takagane3, Y. Okita5, K. Nakamura6, T. Onikubo6, M. Takeuchi7, M. Fujii8, T. Nakajima9, T. Brewer10, M. Sattari11
  • 1Department of Medical Oncology, Kagawa University Hospital, Kida-gun, Japan, /
  • 2Aizawa Hospital, Matsumoto, Japan, /
  • 3Hakodate Goryoukaku Hospital, Hakodate, Japan, /
  • 4Department of Medical Oncology, Kobe City Medical Center General Hospital, Kobe, Japan, /
  • 5Kagawa University Hospital, Kita-gun, Japan, /
  • 6Aizawa Comprehensive Cancer Center, Aizawa Hospital, Matsumoto, Japan, /
  • 7Kitasato University, Minato-ku, Japan, /
  • 8Nihon University School of Medicine, Itabashi-ku, Japan, /
  • 9Japan Clinical Cancer Research Organization, Chuo-ku, Japan, /
  • 10N/A, N/A, /
  • 11University of Florida Health, Gainesville, Florida, USA, /

Abstract

TRIBE trial demonstrated that FOLFOXIRI plus bevacizumab (BV) has higher activity and efficacy compared with FOLFIRI plus BV. Therefore, FOLFOXIRI is regarded as one of the platform regimen of colorectal cancer chemotherapy. However, safety and efficacy of FOLFOXIRI plus panitumumab has not been demonstrated for Japanese patients. We conducted this phase I study to determine the recommended dose of FOLFOXIRI plus panitumumab as first-line treatment of RAS wild-type metastatic colorectal cancer (mCRC).